A Phase 2 interventional study of AMC6156 0.1mg and AMC6156 0.3mg in Sarcopenia in Elderly and Sarcopenia, sponsored by Animuscure Inc.. Recruiting at 4 sites in South Korea. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.
Sponsored by Animuscure Inc. · Phase 2, Interventional, and Treatment
Among 40 studies in Sarcopenia with a site in Korea, Republic of — 13 open to participants now, 15 under way, none of them phase 3. Sarcopenia · Korea, Republic of.
Among the 40 studies in Sarcopenia with a site in Korea, Republic of, this one is the 15th largest by planned enrollment of the 29 interventional ones that give a count, is one of 5 that started in 2025, is one of 5 in phase 2, reaches primary completion later than 9 of the 14 other live ones, and was the 33rd registered.
1,329 studies on the registry are indexed under Sarcopenia; 420 are open to participants now.
Browse Sarcopenia studies →13 of the 40 studies in Sarcopenia with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Pusan National University Yangsan Hospital · Sites in Korea, Republic of
Pluto Inc. · Sites in Korea, Republic of
Seoul National University Bundang Hospital · Sites in Korea, Republic of
Seoul National University Hospital · Sites in Korea, Republic of
Yonsei University · Sites in Korea, Republic of
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 247 Sarcopenia studies recruiting now, 153 (62%) set no upper age limit and 33 (13%) stop at 75 or younger; 9 take children under 18; 65 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 4 3
First in 2009; this study’s year is marked. 5 started in 2025.
This study's planned enrollment of 80 is above the median of 60 across 855 interventional studies indexed under Sarcopenia.
Median enrollment 80 across the 29 interventional studies, 150 across the 11 observational. Of the 19 that completed or were terminated, 2 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 40 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Animuscure Inc. as lead sponsor.
Animuscure Inc. has 1 study filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
3 of the studies in Sarcopenia with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07634523Seoul National University HospitalBranched Chain Amino Acids for Sarcopenia in Patients Undergoing Total Knee Arthroplasty | 2027-05-31 |
| NCT07749118Pusan National University Yangsan HospitalHB05P on Muscle Health | 2027-06-29 |
| NCT07390552Pluto Inc.A Study of PLH-2301 in Subjects With Sarcopenia | 2027-06-30 |
Among the 40 studies in Sarcopenia with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial aims to find out whether AMC6156 can improve physical function and is safe in older adults with sarcopenia. Participants will take AMC6156 or a placebo daily for 12 weeks, and their movement, strength, and safety will be regularly monitored through tests and checkups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: AMC6156 0.1mg
Drug: AMC6156 0.3mg
Drug: AMC6156 1.0mg
Drug: Placebo
Oral administration of AMC6156 in tablet form at a dose of 0.1 mg once daily for 12 weeks.
Oral administration of AMC6156 in tablet form at a dose of 0.3 mg once daily for 12 weeks.
Oral administration of AMC6156 in tablet form at a dose of 1.0 mg once daily for 12 weeks.
Oral administration of placebo tablets matching AMC6156 in appearance, once daily for 12 weeks.
Change in Short Physical Performance Battery (SPPB) Score from Baseline to Week 12
Time frame: At Visit 1 (Screening), Visit 2 (Week 0, Baseline), Visit 3 (Week 4), Visit 4 (Week 8), and Visit 5 (Week 12)
Change in Short Physical Performance Battery (SPPB) Score at Week 4 and Week 8
Time frame: At Visit 1 (Screening), Visit 2 (Week 0, Baseline), Visit 3 (Week 4), Visit 4 (Week 8), and Visit 5 (Week 12)
Change in Timed Up and Go (TUG) Test Time
Time frame: At Visit 2 (Week 0), Visit 3 (Week 4), Visit 4 (Week 8), and Visit 5 (Week 12)
Change in Appendicular Skeletal Muscle Mass (ASM) Measured by DXA
Time frame: At Visit 1 (Screening) and Visit 5 (Week 12)
Change in Handgrip Strength
Time frame: At Visit 1 (Screening), Visit 2 (Week 0) ,Visit 3 (Week 4), Visit 4 (Week 8), and Visit 5 (Week 12)
Change in SARC-F Score
Time frame: At Visit 2 (Week 0) and Visit 5 (Week 12)
Change in Sarcopenia Quality of Life (SarQoL) Score
Time frame: At Visit 2 (Week 0) and Visit 5 (Week 12)
Started Jul 2025 (actual). Primary completion is estimated for Oct 2026, 15 months after the start.
Of 20 phase 2 interventional studies under Sarcopenia, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's planned 15 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.